| Trial name or title |
FOCETELD |
| Methods |
Phase II open‐label, randomised study |
| Participants |
People with KRAS exon 2 WT mCRC, age 70 to 80, ECOG 0 to 1 |
| Interventions |
FOLFIRI with cetuximab (interventional arm), FOLFIRI (control arm) |
| Outcomes |
Primary endpoint: percentage of participants free of disease progression at 6 months. Secondary endpoints: safety of combination of chemotherapy with cetuximab in elderly patients; response rate and median survival in both treatment arms |
| Starting date |
April 2012 |
| Contact information |
Clinica di Oncologia Medica, A.O. Ospedali Riuniti di Ancona, 071.5964169, s.cascinu@univpm.it |
| Notes |
Still "ongoing" on trial database as of March 2017; no further details available at time of publication. |
